Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ACT therapy

- PMLiVE

National Audit Office agrees CDF is ‘unsustainable’

Says a replacement for the CDF is urgently needed

- PMLiVE

First Merck/Samsung biosimilar cleared in South Korea

Approval of Brenzys further opens up competition in biosimilar market

- PMLiVE

NICE hands Merck & Co’s Keytruda speedy recommendation

Cancer drug backed for NHS use against advanced melanoma

- PMLiVE

Pfizer starts Ibrance trials in early breast cancer

Hopes to encourage wider use of breakthrough drug

- PMLiVE

AZ and Peregrine join forces on cancer trial

Another oncology deal for the company after a recent spate of deals

- PMLiVE

FDA grants priority review for new Keytruda licence

Merck’s PD-1 drug being assessed for first-line melanoma patients

- PMLiVE

Novartis licenses cancer support drug from Aveo Oncology

Swiss firm buys into drug to alleviate a wasting syndrome that is seen in chronic patients

Roche Basel Switzerland

Roche’s PD-L1 drug shrinks lung tumours

Drug has already showed success in treating certain bladder cancer patients

- PMLiVE

Ireland’s Mallinckrodt makes $1.3bn immunotherapy purchase

Will acquire Therakos to further boost its hospital drug portfolio

- PMLiVE

BMS launches Opdivo for lung cancer in UK

Drug to be called ‘Nivolumab BMS’ in the country

- PMLiVE

AZ signs two more deals in cancer immunotherapy

Anglo-Swedish firm pens partnerships with Heptares and Mirati Therapeutics

Merck & Co expands board and adds new directors

Appoints Dr Paul Rothman and Pamela Craig

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links